Growth Hormone Secretagogues: What They Are and How They Differ From HGH

People hear "sermorelin," "growth hormone peptides," and "HGH" in the same breath and assume they're versions of the same thing. They aren't. One is a hormone. The other is a signal that asks the body to make more of that hormone on its own. The difference changes what each one can actually do, and it matters if you're trying to understand what a telehealth program is offering you.

HGH is the hormone itself

Synthetic human growth hormone, usually written as HGH or somatropin, is a lab-made copy of the growth hormone your pituitary gland produces. When it's injected, the body receives a set amount of the hormone directly. The dose is the dose. Nothing else has to happen for it to be in your system, because it already is the active substance.

That directness is also why HGH is handled as a prescription medicine rather than a wellness product. Getting it involves a prescriber and a diagnosis, and it is not what the telehealth peptide programs discussed here are offering.

A secretagogue asks the pituitary to respond

Sermorelin belongs to a different class of compound called a growth hormone secretagogue. Specifically, it's an analog of growth-hormone-releasing hormone, or GHRH, the natural signal your hypothalamus sends to your pituitary gland to release growth hormone.

Sermorelin doesn't put growth hormone into your body. It mimics that signal, prompting the pituitary to release its own supply. That's a meaningful distinction: with HGH, you're receiving a fixed amount of the hormone. With a secretagogue, you're sending a request, and the response depends on how much your pituitary is still able to produce and release. A 1997 trial in healthy older men (the primary sources are listed below) found that nightly GHRH 1-29 injections increased nocturnal growth hormone release and peak amplitude over six weeks, but produced no change in IGF-1, IGFBP-3, or how often GH pulses occurred. The signal worked. The downstream hormone levels the researchers tracked didn't move the way a person might assume a "growth hormone product" would move them.

Sermorelin was an approved drug once, and then it wasn't

Sermorelin has a real regulatory history worth knowing. Under the brand name Geref, it was an FDA-approved injection, first approved in December 1990 and later in a second strength in 1997. The manufacturer told the FDA in 2008 that it had discontinued the products, and the approvals were withdrawn effective June 18, 2009.

That withdrawal could look like a safety flag, so the FDA addressed it directly. In a determination published in March 2013, the agency stated that Geref was not withdrawn from sale for reasons of safety or effectiveness. That finding is the step that lets the FDA consider approving a generic version referencing the discontinued product. No such generic has been approved since, so there is no FDA-approved sermorelin product on the market today. The approved version is gone, and what exists today is compounded.

What "compounded" actually means here

When sermorelin is prescribed through a telehealth program today, it's typically prepared by a compounding pharmacy rather than manufactured as an approved drug product. Compounding means a pharmacy mixes or prepares a medication for an individual patient, following a prescription, rather than dispensing a version that went through the FDA's own approval process for that specific drug.

Compounded sterile preparations, including injectables like sermorelin, are expected to follow pharmacy quality standards such as USP General Chapter <797>, which sets requirements for personnel training, facilities, environmental monitoring, and testing meant to prevent contamination or incorrect strength in a sterile compound. Meeting that kind of standard is a pharmacy operations question. It's separate from FDA drug approval, and it doesn't substitute for the clinical trials an approved drug goes through. Being prescribed by a licensed provider and filled at a pharmacy following recognized standards is not the same as the product itself carrying FDA approval, and it's worth understanding that distinction before you look into any secretagogue program.

Why the distinction matters if you're comparing options

If you're weighing HGH against a secretagogue like sermorelin, the difference comes down to this. HGH replaces the hormone directly, at a set dose. A secretagogue asks your own pituitary to release more of it, and how much actually happens depends on the function you still have. That is a different mechanism, a different regulatory status, and a different set of open questions, not a milder version of the same product.

One program built on compounded sermorelin, the Embody Sermorelin program, describes a short online assessment, a review by a licensed provider, and a prescription only if that review supports it. Putting a clinical opinion in front of a prescription is a real check, but it doesn't change what the compound is or settle the pituitary-response question described above.

If you want the fuller picture before comparing programs, our guide to understanding growth-hormone peptides and how they differ from direct hormone products walks through the category in more depth. And if a secretagogue is something you're actually considering, the Embody Sermorelin program page lays out its intake process and pricing directly.

Sources

• Federal Register, "Determination That GEREF (Sermorelin Acetate) Injection... Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness," 2013. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams, regulatory determination on the discontinued branded sermorelin product, not a clinical trial; confirms the 2009 withdrawal was for market reasons, not safety or effectiveness.
• Vittone et al., "Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men," Metabolism, 1997. https://pubmed.ncbi.nlm.nih.gov/9005976/, 11 healthy men aged 64-76 given nightly GHRH 1-29 for 6 weeks; increased nocturnal GH release and peak amplitude, no change in IGF-1, IGFBP-3, or GH pulse frequency; small, short, all-male sample.
• USP General Chapter <797>, Pharmaceutical Compounding, Sterile Preparations. https://www.usp.org/compounding/general-chapter-797, quality standard for sterile compounded preparations; describes expected practices, not proof of any one pharmacy's compliance or of drug efficacy.

Educational content only. Not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, changing, or stopping any medication, peptide, or supplement.